DNA treatment cuts bad cholesterol by nearly 50% without statins

The buzz arrives while traditional statin prescriptions remain common, and the promise of a one‑time treatment appears to challenge that status quo. If the approach lives up to early reports, patients could see fewer medication routines and reduced cardiovascular risk. The approach relies on a DNA‑based nanodrug administered in a single IV infusion, designed to edit the genetic pathways that produce LDL particles.

Researchers describe it as a 'one‑and‑done' gene‑editing trial, aiming to halt the production of bad cholesterol without the need for ongoing pills. Trials reported in the United States, China and British Columbia suggest the injection can lower LDL by nearly half, according to Science Daily and the South China Morning Post. independent.co.uk notes the development of a single jab, while The Daily Scan confirms participation of B.C. researchers in the trial. The Times of India questions whether the effect could be permanent, leaving regulators and clinicians to determine long‑term safety.

Whether the therapy will receive approval and replace statins remains unanswered.